VYNE Therapeutics Inc.VYNENASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank22
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P22
Within normal range
vs 2Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -12.31% |
| Q3 2025 | -0.92% |
| Q2 2025 | -16.64% |
| Q1 2025 | 3.31% |
| Q4 2024 | 6.95% |
| Q3 2024 | -9.85% |
| Q2 2024 | -12.79% |
| Q1 2024 | -2.96% |
| Q4 2023 | 28.22% |
| Q3 2023 | -5.90% |
| Q2 2023 | -0.62% |
| Q1 2023 | -12.69% |
| Q4 2022 | -6.15% |
| Q3 2022 | -8.15% |
| Q2 2022 | -2.54% |
| Q1 2022 | -46.12% |
| Q4 2021 | 65.45% |
| Q3 2021 | 4.07% |
| Q2 2021 | -16.94% |
| Q1 2021 | -67.98% |
| Q4 2020 | -9.43% |
| Q3 2020 | -25.30% |
| Q2 2020 | 4.11% |
| Q1 2020 | 149.85% |
| Q4 2019 | 111.74% |
| Q3 2019 | 27.80% |
| Q2 2019 | 0.35% |
| Q1 2019 | 11.36% |
| Q4 2018 | 10.84% |
| Q3 2018 | -1.78% |
| Q2 2018 | 14.57% |
| Q1 2018 | 58.09% |
| Q4 2017 | 38.03% |
| Q3 2017 | 1.81% |
| Q2 2017 | 19.96% |
| Q1 2017 | -22.03% |
| Q4 2016 | 53.61% |
| Q3 2016 | 0.00% |